Abstract: A device for preventing contamination of a positive-pressure connector (6) of an indwelling needle and a method based on same. The device comprises a shell (1), a connecting port (3) fixedly connected to the shell (1) and used for connecting to the positive-pressure connector (6), an air pressure balance hole (5) disposed opposite to the connecting port (3) and provided on the shell (1), and a filtering membrane (2) provided between the air pressure balance hole (5) and the connecting port (3). The device is simple in structure, adopts a structural design of the filtering membrane (2), can filter microorganisms, bacteria, viruses, dusts, and particulate pollution sources, and is used during indwelling of infusion intervals to prevent the positive-pressure connector (6) from being exposed to the air and maintain the aseptic state and positive-pressure condition of the positive-pressure connector (6) during indwelling.

Abstract: A device for preventing contamination of a positive-pressure connector (6) of an indwelling needle and a method based on same. The device comprises a shell (1), a connecting port (3) fixedly connected to the shell (1) and used for connecting to the positive-pressure connector (6), an air pressure balance hole (5) disposed opposite to the connecting port (3) and provided on the shell (1), and a filtering membrane (2) provided between the air pressure balance hole (5) and the connecting port (3). The device is simple in structure, adopts a structural design of the filtering membrane (2), can filter microorganisms, bacteria, viruses, dusts, and particulate pollution sources, and is used during indwelling of infusion intervals to prevent the positive-pressure connector (6) from being exposed to the air and maintain the aseptic state and positive-pressure condition of the positive-pressure connector (6) during indwelling.

Abstract: The present invention relates to a process for the synthesis of the anti-inflammatory agent 5-chloro-3-(4-methanesulfonylphenyl)-6?-methyl-[2,3?]bipyridine, referred to as compound of formula (1) or etoricoxib, which is a pharmaceutically active ingredient inhibiting cyclooxygenase-2. In particular, the application concerns a novel process of making the compound of formula (1) by oxidizing a compound of formula (4).

Abstract: The present invention relates to a process for the synthesis of the anti-inflammatory agent 5-chloro-3-(4-methanesulfonylphenyl)-6?-methyl-[2,3?]bipyridine, referred to as compound of formula (1) or etoricoxib, which is a pharmaceutically active ingredient inhibiting cyclooxygenase-2. In particular, the application concerns a novel process of making the compound of formula (1) by oxidizing a compound of formula (4).